The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 08, 2020

Filed:

Nov. 20, 2017
Applicants:

Alderbio Holdings Llc, Las Vegas, NV (US);

The University of Iowa Research Foundation, Iowa City, IA (US);

Inventors:

Andrew F. Russo, Iowa City, IA (US);

Eric A. Kaiser, Iowa City, IA (US);

Ana Recober, Iowa City, IA (US);

Adisa Kuburas, Iowa City, IA (US);

Ann C. Raddant, Iowa City, IA (US);

Brian R. Kovacevich, Snohomish, WA (US);

John Latham, Seattle, WA (US);

Jeffrey T. L. Smith, Bellevue, WA (US);

Leon F. Garcia-Martinez, Woodinville, WA (US);

Assignees:

ALDERBIO HOLDINGS LLC, Las Vegas, NV (US);

THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, Iowa City, IA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/26 (2006.01); A61K 31/485 (2006.01); A61K 45/06 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 45/06 (2013.01); C07K 16/26 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); Y02A 50/487 (2018.01);
Abstract

The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.


Find Patent Forward Citations

Loading…